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This special issue of PPAR Research contains an exciting
array ofvaluablereviewsexamining the relationship between
PPARs and various viral infections, varying from HIV to
HCV and HBV. This assembly of reviews includes a group
of three complimentary reviews addressing diﬀerent facets
of the cross-talk between HIV infection and antiretroviral
treatment as well as the potential beneﬁcial role of PPARγ
in HIV-associated lipodystrophy. First, Giralt et al. detail the
cross-talk between HIV infection and PPARγ leading to the
reported negative impact of this interplay on adipose tissue
physiology. They also present literature on the reciprocal,
yet contradictory roles of PPARα and PPARγ on HIV-1
replication and transcription. Second, Caron et al. describe
the eﬀect of ART on adipocyte PPARγ expression in vitro, in
animal models, and in HIV-infected patients. These authors
also report on the intriguing connection between PPARγ,
activated macrophages found in the adipose tissue and ART.
In the third review of this series, J. Sutinen closely examines
the results of 14 diﬀerent clinical trials which evaluated if
the PPARγ thiazolidinedione agonists could be useful in
thetreatmentofHAART-associatedmetaboliccomplications
in HIV-infected patients. Upon careful evaluation of the
reported results, Sutinen concludes that these agonists
produce a very modest, if any, eﬀect on lipoatrophic subcu-
taneous adipose tissue, despite their improvement of insulin
sensitivity in treated patients. The review by Doran and
coworkers focuses on the studies dealing with the potential
role of PPARγ in HIV-1-associated bone disease. These
authors put forth a provocative hypothesis which stipulates
a potential role for PPARγ in the reduced bone mass
associated with HIV-1 infection and treatment. Speciﬁcally,
they suggest a possible dysregulation of the activity of PPARγ
in undiﬀerentiated stromal cells or in partially diﬀerentiated
preosteoblast and preadipocyte cells. The liver which is
impacted not only by HIV but also by HBV and HCV is
the focus of several excellent reviews in this special issue.
In a review by Lemoine and coauthors, the role that PPARs
play in HIV infection, in terms of associated metabolic
disorders, disease progression, coinfections with HBV or
HCV, and response to antiviral treatment, is featured. In
addition, the summary by Lemoine et al. of the experimental
and clinical data regarding PPARS in HIV-associated liver
disease provides a rationale for the use of PPARγ agonists as
therapeutic agents in these patients. Further, Negro reviews
experimental and clinical data suggesting that HCV may
interfere with hepatic insulin signaling, possibly involving
thedownregulationofthePPARγ.Capitalizingontheknown
involvement of PPARs in lipid metabolism, inﬂammatory
process, and ﬁbrogenesis, Dharancy et al. have summarized
experimental and human studies showing a diminished
expression and function of PPARα and PPARγ during HCV
infection. These authors also review the potential beneﬁts
of nonhepatotoxic PPARα/γ agonists as therapeutic agents
to treat chronic hepatitis C. In another valuable review
by Dubuquoy and coauthors, the potential of PPARs to
modulate HBV transcription and replication is summa-
rized. The authors report that, in HBV transgenic mouse
model, activation of PPARα increased the transcription and
replication of HBV, thus concluding that modulating the
PPARα/RXR heterodimer may be an interesting therapeutic
option to control HBV infection. We are assured that the
reviews presented in this special issue, on the interplay2 PPAR Research
between PPARs and viral disease, will be highly useful for
those with interest in the ﬁeld.
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